SWOG S0215: A Phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer

PURPOSE: SWOG trial S0102 showed significant activity of the combination of docetaxel and vinorelbine in HER2-negative metastatic breast cancer (MBC). For HER2-positive patients, additional benefit may occur with the addition of trastuzumab due to its synergy with docetaxel and vinorelbine. DESIGN:...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Livingston, Robert B., Barlow, William E., Kash, Joseph J., Albain, Kathy S., Gralow, Julie R., Lew, Danika L., Flaherty, Lawrence E., Royce, Melanie E., Hortobagyi, Gabriel N.
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3513946/
https://ncbi.nlm.nih.gov/pubmed/21826527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-011-1698-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires